Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of PF-08634404 plus chemotherapy in previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
CTR20262126Phase 2Active
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Pfizer. Started Jun 2026; status: active.
02
Drugs
PF-08634404
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20262126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262126.